Clinical Trials
31 trialsNCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT05312372 2026-02-17
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
Phase 1/2 Withdrawn
NCT05743270 2025-03-11
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Replimune, Inc.
Phase 2 Withdrawn
NCT03197584 2025-02-21
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03554109 2025-02-21
TNBC
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT05998941 2023-11-22
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Withdrawn
NCT05791097 2023-07-24
AdvanTIG-306
Novartis
Phase 3 Withdrawn
NCT05809895 2023-07-24
AdvanTIG-211
Novartis
Phase 2 Withdrawn
NCT04466917 2023-07-03
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
Amgen
Phase 3 Withdrawn
NCT04252768 2023-03-22
AIPAC-002
Immutep S.A.S.
Phase 1 Withdrawn
NCT02569489 2022-07-18
Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
HUYABIO International, LLC.
Phase 1 Withdrawn
NCT04806945 2022-05-05
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT03770299 2022-03-24
CheckMate 9TN
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03400306 2021-12-08
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
AbbVie
Phase 1 Withdrawn
NCT04611776 2021-06-16
CATHAYA
Hoffmann-La Roche
Phase 2 Withdrawn
NCT04203511 2020-06-09
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
Incyte Corporation
Phase 3 Withdrawn
NCT03704077 2020-05-19
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03920839 2020-04-24
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Incyte Corporation
Phase 1 Withdrawn
NCT02929576 2018-10-22
ENDEAR
Pfizer
Phase 3 Withdrawn
NCT02651610 2017-07-11
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Peregrine Pharmaceuticals
Phase 2/3 Withdrawn
NCT01205217 2017-06-07
ELATE
GlaxoSmithKline
Phase 2 Withdrawn
NCT02685306 2017-03-09
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Peregrine Pharmaceuticals
Phase 2 Withdrawn
NCT01702714 2016-11-04
A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease
Hoffmann-La Roche
Phase 1 Withdrawn
NCT01156961 2016-11-02
A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
Hoffmann-La Roche
Phase 4 Withdrawn
NCT01245543 2015-11-02
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Withdrawn
NCT00768131 2015-10-28
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel
Eli Lilly and Company
Phase 2 Withdrawn
NCT01953536 2014-12-19
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Endocyte
Phase 2 Withdrawn
NCT01701349 2014-05-01
FACT2
Mateon Therapeutics
Phase 3 Withdrawn
NCT00055887 2013-05-10
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
Spectrum Pharmaceuticals, Inc
Phase 3 Withdrawn
NCT01137994 2013-03-13
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT01000896 2010-02-04
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
AstraZeneca
Phase 1 Withdrawn